Similar articles

Abstract: Objectives: To investigate the relationship between HBV (hepatitis B virus) polymerase gene 180 and 204 sites mutation and lamivudine resistance. Methods: One hundred forty-one patients with lamivudine resistance after lamivudine treatment and 60 chronic hepatitis B patients without lamivudine treatment were enrolled in this study. The serum HBV DNA mutation was analyzed by sequence detection via polymerase chain reaction (PCR). The sequences of the same patient were analyzed before and after lamivudine treatment. Results: One hundred and nine lamivudine resistance patients had HBV YMDD (tyrosine-methionine-aspartate-aspartate) mutation. Among them, 45 patients had rtL180M/M204V mutation (41.28%), 28 patients had rtL180M/M204I mutation (25.70%) and 36 patients had rtM204I mutation (33.02%). There were 6 patients with rtL180M mutation in 32 lamivudine resistance patients. Sixty chronic hepatitis patients without lamivudine treatment had no mutations. Conclusions: HBV mutations, which play an important role in lamivudine resistance usually locate at polymerase gene 204 site; 180 site mutation was also observed in these patients. Evaluation of the anti-virus therapy by surveillance of the two sites mutations is of importance.

[1] Allen, M.I., Deslauriers, M., Andrews, C.W., Tipples, G.A., Walters, K.A., Tyrell, D.L., Brown, N., Condreay, L.D., 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology, 27(6):1670-1677.

[2] Chayama, K., Suzuki, Y., Kobayashi, M., Tsubota, A., Hashimoto, M., Miyano, Y., Koike, H., 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy. Hepatology, 27(6):1711-1716.

[3] Chen, D.S., 1993. From hepatitis to hepatoma: Lessons from type B viral hepatitis. Science, 262(5132):369-370.

[4] Chu, C.M., Liaw, Y.F., 1997. Natural history of chronic hepatitis B virus infection: An immunopathological study. J Gastroenterol Hepatol, 12(9-10):S218-S222.

[5] Dienstag, J.L., Schiff, E.R., Wright, T.L., Perrillo, R.P., Hann, H.W., Goodman, Z., 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med, 341(17):1256-1263.

[6] Gutfreund, K.S., Williams, M., George, R., Bain, V.G., Ma, M.M., Yoshida, E.M., 2000. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol, 33(3):469-475.

[7] Kirishima, T., Okanoue, T., Daimon, Y., Itoh, Y., Nakamura, H., Morita, A., 2002. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 37(2):259-265.

[8] Kobayashi, S., Ide, T., Sata, M., 2001. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol, 34(4):584-586.

[9] Lai, C.L., Ching, C.K., Tung, A.K.M., Li, E., Young, J., Hill, A., 1997. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial. Hepatology, 25(1):241-244.

[10] Lai, C.L., Chien, R.N., Leung, N.W., Chang, T.T., Guan, R., Tai, D.I., 1998. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med, 339(2):61-68.

[11] Lee, W.M., 1997. Hepatitis B virus infection. N Engl J Med, 337(24):1733-1745.

[12] Leung, N., 2002. Treatment of chronic hepatitis B: Case selection and duration of therapy. J Gastroenterol Hepatol, 17(4):409-414.

[13] Pillay, D., Bartholomeusz, A., Cane, P.A., Mutimer, D., Schinazi, R.F., Locarnini, S.A., 1998. Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance. Int Antiviral News, 6:167-169.

[14] Stuyver, L.J., Locarnini, S.A., Lok, A., Richmann, D.D., Carman, W.F., Dienstag, J.L., 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology, 33(3):751-757.

[15] Yeh, C.T., Chien, R.N., Chu, C.M., Liaw, Y.F., 2000. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology, 31(6):1318-1326.